Abstract
The tyrosine kinase epidermal growth factor receptor (EGFR) has emerged in recent years as a key and validated target of targeted therapies for solid tumors. It plays a central role in oncology since it is involved in many steps of tumor progression such as proliferation, angiogenesis, invasiveness, decreased apoptosis, and loss of differentiation. Recent advances in targeted therapies have demonstrated that tyrosine kinase inhibitors (TKIs), have provided a marked benefit to subsets of patients whose tumors harbor specific genetic abnormalities. However, resistance phenomenon appears rapidly and patients with EGFR mutations acquire resistance to TKI inhibitors decreasing therefore the median time to disease progression to few months. Several strategies were envisioned to overcome this resistance, such as dual–target inhibitors, multitarget and combined therapy. This review summarizes recent advances in TKIs development with special focus on rational strategies for the design of potent EGFR inhibitors including molecular modeling studies based on crystallographic data. Such advances open the way for new research possibilities in modern medicinal chemistry combined to structure-based drug design.
Keywords: Breast cancer, drug design, EGFR, irreversible inhibitors, NSCLC, mutation, reversible inhibitors
Current Medicinal Chemistry
Title:Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Volume: 20 Issue: 16
Author(s): P. Warnault, A. Yasri, M. Coisy-Quivy, G. Cheve, C. Bories, B. Fauvel and R. Benhida
Affiliation:
Keywords: Breast cancer, drug design, EGFR, irreversible inhibitors, NSCLC, mutation, reversible inhibitors
Abstract: The tyrosine kinase epidermal growth factor receptor (EGFR) has emerged in recent years as a key and validated target of targeted therapies for solid tumors. It plays a central role in oncology since it is involved in many steps of tumor progression such as proliferation, angiogenesis, invasiveness, decreased apoptosis, and loss of differentiation. Recent advances in targeted therapies have demonstrated that tyrosine kinase inhibitors (TKIs), have provided a marked benefit to subsets of patients whose tumors harbor specific genetic abnormalities. However, resistance phenomenon appears rapidly and patients with EGFR mutations acquire resistance to TKI inhibitors decreasing therefore the median time to disease progression to few months. Several strategies were envisioned to overcome this resistance, such as dual–target inhibitors, multitarget and combined therapy. This review summarizes recent advances in TKIs development with special focus on rational strategies for the design of potent EGFR inhibitors including molecular modeling studies based on crystallographic data. Such advances open the way for new research possibilities in modern medicinal chemistry combined to structure-based drug design.
Export Options
About this article
Cite this article as:
Warnault P., Yasri A., Coisy-Quivy M., Cheve G., Bories C., Fauvel B. and Benhida R., Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors, Current Medicinal Chemistry 2013; 20 (16) . https://dx.doi.org/10.2174/0929867311320160001
DOI https://dx.doi.org/10.2174/0929867311320160001 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science Design and Synthesis of Novel Thioethers Derived from 1,5-Diphenyl-6- thioxo-6,7-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones as Antiangiogenic Agents
Letters in Drug Design & Discovery Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Current Drug Metabolism Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals Progress on Multi-Modality Molecular Imaging
Current Medical Imaging A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets The Other Side of the Opioid Story: Modulation of Cell Growth and Survival Signaling
Current Medicinal Chemistry Liver Stem Cells: From Preface to Advancements
Current Stem Cell Research & Therapy Role of Inflammatory Cells and Toll-Like Receptors in Atherosclerosis
Current Vascular Pharmacology Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs
Letters in Drug Design & Discovery The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Potential Approaches for Beta Cell Imaging with PET and SPECT
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Linear Peptides in Intracellular Applications
Current Medicinal Chemistry HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Synthesis, Molecular Docking Study, and Cytotoxic Activity of 3,4-diaryl-5-(4-pyridinyl)-1,2,4-oxadiazole
Medicinal Chemistry Nutraceuticals for Protection and Healing of Gastrointestinal Mucosa
Current Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology